Related Experiment Video

Updated: Jun 4, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

FMS-like tyrosine kinase 3 inhibitors: a patent review

Jongkook Lee1, Seung-Mann Paek, Sun-Young Han

  • 1Korea Research Institute of Chemical Technology, Bio-organic Science Division, Daejeon 305-600, Republic of Korea.

Expert Opinion on Therapeutic Patents
|February 18, 2011
PubMed
Abstract

Insights

FMS-like tyrosine kinase 3 (Flt3) inhibitors show promise for acute myeloid leukemia (AML) treatment. Further research into diverse Flt3 inhibitors is needed to overcome unavoidable relapse and resistance in AML patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • FMS-like tyrosine kinase 3 (Flt3) mutations are prevalent in acute myeloid leukemia (AML).
  • Current AML therapies exhibit limited efficacy and significant toxicity, highlighting an unmet need for improved treatments.
  • Flt3 inhibitors represent a promising therapeutic strategy for AML, particularly for patients with Flt3 mutations.

Purpose of the Study:

  • To provide a comprehensive review of Flt3 inhibitor patents.
  • To summarize current clinical developments and research findings on Flt3 inhibitors in AML.
  • To discuss the potential and limitations of Flt3 inhibitors in AML therapy.

Main Methods:

  • Systematic review of Flt3 inhibitor patents.
  • Analysis of original research articles from peer-reviewed journals.
  • Compilation of data from current clinical trials and development resources.

Main Results:

  • Recent preclinical and clinical trials have advanced the understanding of Flt3 inhibitors.
  • Some Flt3 inhibitors demonstrate notable efficacy in AML patients.
  • Relapse and resistance to Flt3 inhibitors remain significant challenges in AML treatment.

Conclusions:

  • Continued exploration of structurally diverse Flt3 inhibitors is crucial.
  • Inhibitors targeting both wild-type and mutated Flt3 are needed to overcome resistance.
  • Further research is essential to develop more effective and durable therapies for AML.

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...